James Dean, MD, senior medical director at Pharmacyclics provides an update on the most recent long-term data showing ibrutinib to be safe and effective for treating patients with chronic lymphatic leukemia (CLL).
CLL is a rare blood cancer resulting in a build-up of lymphocytes in bone marrow, lymph nodes and blood. In the United States, an estimated 20,000 new cases of CLL will be diagnosed in 2019. The disease is considered treatable, but relapse is very common.
Ibrutinib is a Bruton tyrosine kinase inhibitor approved to treat patients with CLL. It is also approved to treat small lymphocytic lymphoma Waldenstrom macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and chronic graft-versus-host disease.
Among the data discussed by Dr. Dean is extended follow-up analysis of the Phase 3 E1912 clinical study – designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) – comparing ibrutinib plus rituximab to a standard chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) for previously untreated patients with CLL aged 70 years or younger. These results were featured today in the CLL.
New data from the RESONATE studies also showed the value of ibrutinib monotherapy in CLL patients and data from the showed the potential value of ibrutinib in combination with venetoclax in the ongoing CAPTIVATE study.
To stay up to date on the latest clinical developments, be sure to sign up to our newsletter at checkrare.com/sign-up